Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Aug 20, 2025

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.1K

Multiple sclerosis progression: time for a new mechanism-driven framework.

Tanja Kuhlmann1, Marcello Moccia2, Timothy Coetzee3

  • 1Institute of Neuropathology, University Hospital Münster, Münster, Germany; Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.

The Lancet. Neurology
|November 21, 2022
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis - Authors' reply.

The Lancet. Neurology·2026
Same author

Anti-Nogo-A NG101 treatment induces changes in spinal cord micro- and macrostructure following spinal cord injury.

Nature communications·2026
Same author

Performance of the 2024 McDonald Criteria in Patients Under Evaluation for Suspected Multiple Sclerosis.

Neurology·2026
Same author

Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2025
Same author

Spatially-restricted inflammation-induced senescent-like glia in multiple sclerosis and patient-derived organoids.

Nature communications·2025
Same journal

Resolution of expression of concern-Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.

The Lancet. Neurology·2026
Same journal

UCL Queen Square Institute of Neurology: 75 years of innovation.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 631.

The Lancet. Neurology·2026
Same journal

Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2025; 24: 740-52.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 357-67.

The Lancet. Neurology·2026
See all related articles
This summary is machine-generated.

Multiple sclerosis progression is better viewed as a continuum, not distinct stages. Understanding this spectrum of pathological and compensatory processes can improve patient care and treatment targets.

Area of Science:

  • Neurology
  • Neuroimmunology
  • Pathophysiology

Background:

  • Multiple sclerosis (MS) traditionally classified by clinical subtypes: relapsing-remitting (RRMS), secondary progressive (SPMS), and primary progressive (PPMS).
  • These classifications guide patient care, research, and drug approvals.
  • Emerging evidence suggests MS is a continuum rather than discrete stages.

Purpose of the Study:

  • To propose a new conceptualization of multiple sclerosis course as a spectrum.
  • To highlight the role of overlapping pathophysiological and compensatory processes in MS progression.
  • To emphasize the impact of aging on neural injury and resilience in MS.

Main Methods:

  • Review of accumulating evidence on MS pathophysiology.
  • Analysis of the shift from acute injury to widespread inflammation and neurodegeneration.

More Related Videos

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.7K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

935

Related Experiment Videos

Last Updated: Aug 20, 2025

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.1K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.7K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

935
  • Consideration of compensatory mechanisms like neuroplasticity and remyelination.

    • Main Results:

    • The clinical course of MS reflects a continuum influenced by varying pathological and compensatory processes.
    • Progression involves a shift from localized injury to widespread inflammation, neurodegeneration, and impaired compensatory mechanisms.
    • Aging exacerbates neural susceptibility and reduces resilience in MS patients.

    Conclusions:

    • Reconsidering MS as a spectrum defined by the interplay of pathological and reparative processes is encouraged.
    • New insights into progression mechanisms and quantification hold promise for clinical care and treatment strategies.
    • This paradigm shift may inform future therapeutic targets and regulatory decision-making for MS treatments.